Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-induced osteomalacia: a 2026 update.

Minerva medica·2026
Same author

Clarifying the romosozumab "Super-Responder" phenotype: response to methodological concerns.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Adrenalectomy improves cardiovascular profile in patients with mild autonomous cortisol secretion: extension of a multicenter randomized controlled trial to 12 months.

Journal of endocrinological investigation·2026
Same author

Clinical features of Italian adult individuals with X-linked hypophosphatemia: a multicenter retrospective study.

Endocrine connections·2026

Related Experiment Video

Updated: May 22, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Bone involvement in aldosteronism.

Antonio Stefano Salcuni1, Serena Palmieri, Vincenzo Carnevale

  • 1Endocrinology Unit, Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo (FG), Italy.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|May 17, 2012
PubMed
Summary
This summary is machine-generated.

Primary aldosteronism (PA) is linked to lower bone mineral density and higher rates of osteoporosis and fractures. Treatment for PA can improve bone health markers and bone density.

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 22, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Mineralocorticoid Excess

Background:

  • Aldosteronism is associated with reduced bone mineral density (BMD) and cortical bone strength in animal models.
  • Primary aldosteronism (PA) is an endocrine disorder characterized by excessive aldosterone secretion.
  • The impact of PA on bone health in humans requires further investigation.

Purpose of the Study:

  • To evaluate bone involvement in patients diagnosed with primary aldosteronism (PA).
  • To compare bone mineral density (BMD), biochemical profiles, and fracture prevalence between PA patients and a control group.

Main Methods:

  • 188 subjects with adrenal incidentaloma were screened for PA.
  • 11 PA patients and 15 non-PA (nPA) patients underwent biochemical testing, BMD measurement (dual X-ray absorptiometry), and spinal radiography.
  • Statistical analyses included comparative tests and logistic regression.

Main Results:

  • PA patients exhibited higher 24-hour urinary calcium and parathyroid hormone (PTH) levels compared to nPA patients.
  • BMD at the lumbar spine, femoral neck, and total hip was significantly lower in PA patients.
  • Osteoporosis prevalence was higher in PA patients (72.7% vs. 20.0%), with a trend towards more vertebral fractures (45.5% vs. 13.3%).
  • Osteoporosis and vertebral fractures were independently associated with PA.
  • Treatment of PA led to reduced urinary calcium and PTH, and increased BMD over time.

Conclusions:

  • Primary aldosteronism is associated with reduced bone mineral density, increased osteoporosis, and a higher prevalence of vertebral fractures.
  • Elevated urinary calcium excretion and PTH levels are characteristic biochemical findings in PA patients with bone involvement.
  • Treatment of PA demonstrates potential for improving bone health parameters.